Pharmaceuticals Announces Second Quarter

Pharmaceuticals Announces Second Quarter

Fiscal Year 2019 Financial Results

Company will host a business update conference call on February 19, 2019 at 4:30 PM Eastern Time -

VANCOUVER, British Columbia and MENLO PARK,

California, February 12, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"),

a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the second

quarter ended December 31, 2018. DelMar executive management will host a business update conference call for investors, analysts

and other interested parties on February 19, 2019 at 4:30 p.m. Eastern Time.

quarter, we continued enrollment in our Phase 2 clinical trials for MGMT-unmethylated GBM patients at the MD Anderson Cancer Center

in Houston, Texas, and at Sun Yat-sen University Cancer Center in Guangzhou, China," commented Saiid Zarrabian, President

and Chief Executive Officer of DelMar Pharmaceuticals. "We are now nearing full enrollment at MD Anderson and halfway enrollment

in China. We are eagerly anticipating data from each of these studies."

For further details on the Company's operating

and financial results, as well as more detail about its updated strategy, refer to DelMar's Form 10-K filed with the SEC

on September 24, 2018, as well as the Company's Quarterly Report on Form 10-Q for the three and six months ended December

31, 2018 filed with the SEC on February 11, 2019:

http://ir.delmarpharma.com/all-sec-filings.

CONFERENCE CALL DETAILS

DelMar will host a conference call to discuss its financial

results for quarter ended December 31, 2018 and provide a corporate update on February 19, 2019, at 4:30 p.m. Eastern Time. For

both "listen-only" participants and those who wish to take part in the question and answer portion of the call, the

telephone Dial-in Number is 1-877-876-9174 (toll free) with Conference ID DELMAR.

A replay of the conference call will be available on the IR

Calendar of the Investors section of the Company's website at www.delmarpharma.com and will be archived for 30 days.

SUMMARY OF FINANCIAL RESULTS FOR PERIODS ENDED DECEMBER 31,

At December 31, 2018, the Company had cash

and cash equivalents on hand of approximately $3.7 million.

For the three months ended December 31,

2018, the Company reported a net loss of $1,809,697, or $0.08 per share, compared to a net loss of $3,161,598, or $0.14 per share,

for the three months ended December 31, 2017.

For the six months ended December 31, 2018,

the Company reported a net loss of $3,801,501, or $0.16 per share, compared to a net loss of $5,828,004, or $0.31 per share, for

the six months ended December 31, 2017.

The following represents selected financial

information as of December 31, 2018. The Company's financial information has been prepared in accordance with U.S. GAAP and

this selected information should be read in conjunction with DelMar's consolidated financial statements and management's

discussion and analysis, as filed.

DelMar's financial statements as filed with the U.S. Securities

Exchange Commission can be viewed on the company's website at: http://ir.delmarpharma.com/all-sec-filings.

Selected Balance Sheet Data

Selected Statement of Operations Data

For the three months ended:

Research and development expenses decreased to $947,249 during

the three months ended December 31, 2018 from $2,141,945 for the three months ended December 31, 2017. The decrease was largely

attributable to a decrease in clinical development costs, personnel, preclinical research, and non-cash, share-based compensation

expense during the three months ended December 31, 2018 compared to the three months ended December 31, 2017.

General and administrative expenses decreased during the three

months ended December 31, 2018 to $874,884 from $1,011,879 for the three months ended December 31, 2017, largely due to a decrease

in professional fees and personnel, partially offset by higher non-cash, share-based compensation expense in the current quarter

compared to the prior quarter.

For the six months ended:

Research and development expenses decreased to $1,966,369 during

the six months ended December 31, 2018 from $4,076,588 for the six months ended December 31, 2017. The decrease was largely attributable

to a decrease in clinical development costs, personnel, preclinical research, intellectual property and travel costs during the

current period compared to the prior period.

General and administrative expenses were $1,861,354 for the

six months ended December 31, 2018 compared to $1,756,500 for the six months ended December 31, 2017. A significant portion of

the increase was due to an increase in non-cash, share-based compensation expense and personnel costs in the current period compared

to the prior period. Partially offsetting the impact of these two items were lower professional fees and travel costs during the

six months ended December 31, 2018 compared to the six months ended December 31, 2017.

Pharmaceuticals, Inc.

DelMar is focused on the development and

commercialization of new therapies for cancer patients who have limited or no treatment options. By focusing on understanding tumor

biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies in indications where

patients are failing, or are unable to tolerate, standard-of-care treatments.

The Company's current pipeline is

based around VAL-083, a "first-in-class," small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated

clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder

cancer, head & neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on DelMar's internal

research programs, and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development

and commercialization of VAL-083 to solve significant unmet medical needs.

VAL-083 is being studied in two collaborator-supported,

biomarker-driven, Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance represents a significant

unmet medical need in the treatment of GBM. In addition, DelMar has announced the allowance of a separate IND for VAL-083 as a

potential treatment for platinum-resistant ovarian cancer.

Further information on DelMar's clinical

trials can be found on clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs

For additional information, please visit http://delmarpharma.com/;

or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989.

Connect with the Company on Twitter, LinkedIn,

Facebook, and Google+.

Safe Harbor Statement

contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is

defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current

expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ

materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability

to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and

technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research

and development, clinical studies and future product commercialization; and, the Company's business, research, product development,

regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more

detail in the Company's filings with the SEC, including, the Company's Annual Report on Form 10-K for the year ended

June 30, 2018, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports on Form 8-K.